H. Lundbeck A/S
OTC: HLUBF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Charl van Zyl
- Employees
- 5,127
- Headquarters
- Valby, Denmark
- IPO year
- 2022
- Market cap
- $5.8B
- Website
- https://www.lundbeck.com
Loading HLUBF…
Loading profile data…Frequently asked questions about HLUBF
What does H. Lundbeck A/S (HLUBF) do?
H. Lundbeck A/S engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders. Its product portfolio targets the following diseases: Alzheimer's, depression, Parkinson's, Schizophrenia, alcohol dependence, anxiety, bipolar disorder, epilepsy, and Huntington's. It operate...
Where does HLUBF trade?
H. Lundbeck A/S (HLUBF) trades on the Other OTC.
What sector is HLUBF in?
H. Lundbeck A/S (HLUBF) operates in the Healthcare sector, specifically in the Medical - Pharmaceuticals industry.
Who is the CEO of H. Lundbeck A/S?
Charl van Zyl is the chief executive officer of H. Lundbeck A/S (HLUBF).
Where is H. Lundbeck A/S headquartered?
H. Lundbeck A/S is headquartered in Denmark.
Does HLUBF pay a dividend?
Yes — H. Lundbeck A/S (HLUBF) paid a trailing twelve-month dividend of USD 0.18 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did HLUBF go public?
H. Lundbeck A/S (HLUBF) completed its initial public offering in 2022.